A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

PHASE3CompletedINTERVENTIONAL
Enrollment

813

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

IDP-123 Lotion

Tazarotene 0.045% Lotion

DRUG

IDP-123 Vehicle Lotion

Vehicle Lotion

Trial Locations (45)

10022

Valeant site 20, New York

10075

Valeant Site 36, New York

22434

Valeant Site 01, San Diego

23507

Valeant Site 45, Norfolk

27262

Valeant Site 09, High Point

30263

Valeant Site 26, Newnan

32174

Valeant Site 33, Ormond Beach

32771

Valeant Site 13, Sanford

33028

Valeant Site 27, Pembroke Pines

33162

Valeant Site 40, North Miami Beach

33401

Valeant Site 03, West Palm Beach

33486

Valeant Site 35, Boca Raton

37215

valeant Site 14, Nashville

37917

Valeant Site 34, Knoxville

40217

Valeant Site 22, Louisville

43016

Valeant Site 11, Dublin

45236

Valeant Site 32, Cincinnati

46617

Valeant Site 17, South Bend

47150

Valeant Site 23, New Albany

48088

Valeant Site 16, Warren

48202

Valeant Site 38, Detroit

60005

Valeant Site 06, Arlington Heights

66215

Valeant Site 31, Overland Park

70006

Valeant Site 08, Metairie

71913

Valeant Site 24, Hot Springs

75093

Valeant Site 18, Plano

77494

Valeant Site 05, Katy

77598

Valeant Site 43, Webster

78213

Valeant Site 25, San Antonio

78759

Valeant Site 12, Austin

80033

Valeant Site 37, Wheat Ridge

83704

Valeant Site 30, Boise

84114

Valeant Site 41, Salt Lake City

85032

Valeant Site 19, Phoenix

Valeant Site 21, Phoenix

90266

Valeant Site 02, Manhattan Beach

91942

Valeant Site 04, La Mesa

92562

Valeant Site 42, Murrieta

95819

Valeant Site 39, Sacramento

97030

valeant Site 07, Gresham

99202

Valeant Site 44, Spokane

02919

Valeant Site 15, Johnston

K9J5K2

Valeant Site 29, Peterborough

N2J1C4

Valeant Site 28, Waterloo

H7E0E3

Valeant Site 10, Laval

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03168321 - A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301) | Biotech Hunter | Biotech Hunter